ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 20,700 shares, an increase of 38.9% from the June 30th total of 14,900 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average trading volume of 31,000 shares, the days-to-cover ratio is currently 0.7 days.

A number of institutional investors and hedge funds have recently made changes to their positions in ICCC. BlackRock Inc. grew its stake in ImmuCell by 601.1% in the 1st quarter. BlackRock Inc. now owns 12,831 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 11,001 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of ImmuCell in the second quarter valued at approximately $58,000. Finally, Renaissance Technologies LLC grew its stake in ImmuCell by 14.6% in the fourth quarter. Renaissance Technologies LLC now owns 110,106 shares of the biotechnology company’s stock worth $567,000 after purchasing an additional 14,000 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of ImmuCell from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Aegis initiated coverage on shares of ImmuCell in a research note on Monday, July 13th. They issued a “buy” rating and a $14.00 price objective for the company.

ICCC opened at $4.98 on Friday. The business has a fifty day moving average of $5.23 and a 200 day moving average of $4.79. The stock has a market cap of $35.92 million, a P/E ratio of -20.75 and a beta of 1.46. The company has a quick ratio of 5.02, a current ratio of 5.88 and a debt-to-equity ratio of 0.28. ImmuCell has a 52-week low of $3.70 and a 52-week high of $8.13.

ImmuCell (NASDAQ:ICCC) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The business had revenue of $4.91 million for the quarter. ImmuCell had a negative return on equity of 5.35% and a negative net margin of 10.98%. Equities analysts anticipate that ImmuCell will post -0.23 EPS for the current fiscal year.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

See Also: Does the discount rate affect the economy?

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.